Letters

The Inhibitory Effects of Cannabidiol on Systemic Malignant Tumors

To the Editor:

The recent article by Johnson et al. provided for highly stimulating reading. Cannabidiol may attenuate tumor growth in a number of other systemic malignancies. Decreased tumor growth in pulmonary malignancies is seen after administration of cannabidiol. Cannabidiol increases the expression of cyclooxygenase-2 within the cancerous cells. Cannabidiol also induces tissue inhibitor of metalloproteinase-1 synthesis and activity. Peroxisome proliferator-activated receptor-gamma expression is augmented at the same time. Intercellular adhesion molecule-1 induction also is seen typically. As a result, intratumoral apoptosis is markedly accentuated. Cannabidiol also downregulates the expression of plasminogen activator inhibitor-1. Increased nuclear translocation of peroxisome proliferator-activated receptor-gamma accompanies the above changes. Tumor metastasis also is markedly attenuated.

Similar attenuation of tumor growth is seen in breast malignancies. It mediates this anti-neoplastic effect by attenuating mammalian target of rapamycin signaling. Endoplasmic reticulum stress is typically accentuated and the cytoplasmic release of cytochrome C is markedly enhanced. ID1 expression also is inhibited at the same time. On the other hand, ID2 expression is markedly upregulated. AKT inhibition accompanies the above changes. As a consequence, there is both increased apoptosis and intratumoral autophagy. Interestingly, beclin-1 plays a major role in these changes.

The above examples clearly illustrate the significant antineoplastic effects of cannabidiol. Hopefully, the next few years will see increased studies to fully and further evaluate these antineoplastic effects.

Shailendra Kapoor, MD
Chicago, Illinois, USA
http://dx.doi.org/10.1016/j.jpainsymman.2013.02.002

References


